Health Care · Pharmaceutical Preparations

IMNM Immunome Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 147201291 filings
Russell 2000

IMNM at a glance

Immunome Inc. (IMNM, SEC CIK 1472012) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as September 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Immunome Inc. (IMNM) reported revenue of $6.9 million (down 23.2% from FY2024) and a net loss of $212.4 million. Diluted EPS was -$2.43.
  • The most recent insider open-market sale reported on Form 4 was by Higgins Jack on September 11, 2026 of 13,200 shares at $25.32 per share.
  • In the last 90 days, IMNM insiders reported 0 open-market purchases ($0) and 1 open-market sale ($334K) on Form 4, a net sale of $334K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$6.9M
−23.2% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$334K
Latest 8-K
Nov 9, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Development and commercialization of first- and best-in-class targeted oncology therapies with focus on antibody-drug conjugates (ADCs) and radioligand therapies (RLTs)
  • New emphasis on varegacestat for desmoid tumors with positive Phase 3 results and planned NDA submission Q2 2026
  • Strategic shift to advancing innovative pipeline including IM-1021 (ROR1 ADC in Phase 1) and IM-3050 (FAP-targeted RLT with IND clearance in April 2025)
  • Pipeline breadth: 3 clinical and 3 preclinical assets; positive Phase 3 topline for varegacestat showing 84% PFS risk reduction (HR=0.16, p<0.0001)
  • Noteworthy: Acquisition of varegacestat from Ayala Pharmaceuticals in March 2024 and fastest pivotal study hazard ratio reported in desmoid tumor population

Risk Factors

  • Cybersecurity risk with potential regulatory fines, litigation, operational disruption, and reputational harm from IT system compromises
  • Key-person dependency on three senior IT officers managing cybersecurity, including Head of IT and Senior Director with 30+ years biotech experience
  • Board audit committee oversight of cybersecurity risk management and incident reporting, with escalation protocols for material cyber threats

Management Discussion & Analysis

  • Collaboration revenue $6.9M, down $2.1M YoY from $9.0M, ceasing after July 2025 termination
  • Operating margin improvement: operating loss $224.1M vs $305.8M, R&D expenses up to $177.3M vs $129.5M, G&A $43.8M vs $33.0M
  • Best segment: Varegacestat R&D $52.4M, up $24.4M YoY; Worst segment: IM-1021 R&D $11.0M, down $13.1M YoY
  • Cash flow 2025: Operating cash use $190.9M vs $110.8M; Financing inflows $640.4M (public offerings and ATM); Capex $9.7M and IPR&D purchase $6.2M
  • Outlook: NDA submission for varegacestat Q2 2026; Increased R&D and G&A expected for clinical advancement and commercialization; Additional financing likely needed beyond 12 months

AI summary of the IMNM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added: IM-3050 Lu-177 program, limited qualified radioactive-material suppliers delayed its Phase 1 trial
  • Regulatory: FDA NDA for varegacestat assigned April 28, 2027 PDUFA date, but approval remains uncertain
  • Compliance: EU AI Act exposure, noncompliance penalties up to €35 million or 7% of worldwide annual turnover
  • Operational: Diagnostic radiotracer shipment delays impaired IM-3050 Phase 1 trial commencement
  • Financial: Accumulated deficit $940.9 million, with cash, equivalents and marketable securities funding at least 12 months

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales or collaboration revenue
  • Net loss $85.8M vs $57.5M YoY, operating loss $90.4M vs $60.1M
  • Highest R&D spend IM-1021 at $9.6M, up $6.7M YoY; lowest IM-1617 at $1.6M, down $3.8M
  • Cash and equivalents $212.8M, marketable securities $248.7M; operating cash use $181.1M for nine months
  • Existing liquidity sufficient for at least 12 months; additional financing needed, with rising development and commercialization costs

AI summary of the IMNM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026 announced
  • Business update included alongside quarterly financial results

Item EX-99.1: Item EX-99.1

  • Q3 2026 net loss $85.8M, with operating expenses $90.4M versus $60.1M year over year
  • Cash, equivalents and marketable securities $461.6M, expected to fund operations into 2028
Filed Oct 5, 2026Full analysis →

Item 3.02: Unregistered Sales of Equity Securities

  • Immunome issued shares to Bristol Myers Squibb under a Stock Issuance Agreement, creating potential dilution for existing shareholders
  • Private-placement exemption under Securities Act Section 4(a)(2), avoiding immediate public registration

Item 1.01: Entry into a Material Definitive Agreement

  • $20.0M cash plus 4,425,487 shares paid to BMS for full ownership of varegacestat and AL101 patent rights
  • Elimination of all future milestone, royalty and other BMS payment obligations improves economics of the programs
Filed Aug 11, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA accepted varegacestat NDA; PDUFA decision target April 28, 2027, creating a defined regulatory catalyst
  • Phase 3 RINGSIDE showed 84% lower progression-or-death risk and 56% objective response rate versus 9% placebo

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026 announced
  • Business update included in Exhibit 99.1 press release

AI summaries of IMNM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IMNM

Don't miss the next IMNM filing

  • Alerts as it files. A push when IMNM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IMNM, by share count.
  • Ask anything. An AI agent that reads every IMNM filing and answers with sources.

IMNM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Higgins JackMSep 11, 2026$1.35
Higgins JackSellSep 11, 2026$25.32
Higgins JackGSep 11, 2026-
Higgins JackMSep 11, 2026-
Barchas IsaacSellAug 12, 2026$27.25
Barchas IsaacSellAug 11, 2026$26.23
Barchas IsaacSellAug 10, 2026$26.07
Barchas IsaacSellAug 7, 2026$26.06

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$9.0M$6.9M
Operating Income-$109.5M-$305.8M-$224.1M
Net Income-$106.8M-$293.0M-$212.4M
Op. Margin--3382.4%-3228.8%
Net Margin--3240.4%-3060.0%
Balance Sheet
Total Assets-$240.2M$683.2M
Equity-$181.2M$634.3M
ROE--161.7%-33.5%
Per Share
EPS$-5.38$-5.00$-2.43
Cash Flow
Operating CF-$7.6M-$110.8M-$190.9M
CapEx-$7.2M$9.7M

Source: XBRL data in Immunome Inc. (IMNM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

IMNM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
8-KOct 5, 2026Analysis-
4Sep 15, 2026--
4Aug 12, 2026--
8-KAug 11, 2026Analysis-
10-QAug 11, 2026Analysis
4Aug 10, 2026--
4Aug 6, 2026--
4Jul 27, 2026--
4Jul 27, 2026--
4Jul 27, 2026--
4Jul 27, 2026--
4Jul 27, 2026--
4Jul 27, 2026--
4Jul 27, 2026--
4Jul 9, 2026--
4Jul 7, 2026--
4Jul 7, 2026--
4Jul 2, 2026--
4Jun 29, 2026--
4Jun 17, 2026--
8-KJun 12, 2026Analysis-
4Jun 12, 2026--
4Jun 12, 2026--

Related Health Care companies

All Health Care →

IMNM SEC filings: frequently asked questions

Are IMNM insiders buying or selling?

In the last 90 days, Immunome Inc. (IMNM) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $334,224 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

What was IMNM's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Immunome Inc. (IMNM) reported revenue of $6.9 million (down 23.2% from FY2024) and a net loss of $212.4 million. Diluted EPS was -$2.43. The figures come from the XBRL data in the 10-K.

What are the main risks in IMNM's latest 10-K?

In the 10-K filed March 3, 2026, Immunome Inc. (IMNM) flagged: Cybersecurity risk with potential regulatory fines, litigation, operational disruption, and reputational harm from IT system compromises. Key-person dependency on three senior IT officers managing cybersecurity, including Head of IT and Senior Director with 30+ years biotech experience. (AI summary of the Risk Factors section.)

What did IMNM report in its latest 8-K?

Immunome Inc. (IMNM) filed an 8-K on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results for quarter ended September 30, 2026 announced.

What are the latest IMNM SEC filings?

Immunome Inc. (IMNM) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on September 15, 2026.

What is IMNM's SEC CIK number?

Immunome Inc. (IMNM)'s SEC Central Index Key (CIK) is 1472012. EDGAR lists every IMNM filing under that number.

Ask anything about IMNM

The research agent reads IMNM's filings, financials, insider trades and 13F holders, then answers with sources.